Product Images Sevelamer Carbonate

This is a set of labels for Sevelamer Carbonate Tablets, 800 mg, packaged by American Health Packaging in Columbus, OH 43217. The labels show different LOT numbers and EXPIRY dates for each batch of tablets. The label also contains a barcode (01)00360857520331 and (07)00350887228331 for LOT numbers x000xx and XXX respectively, which can be scanned for inventory control purposes.*

Sevelamer Carbonate is a prescription drug available in tablet form. Each tablet contains 800 mg of SRR carbonate. Inactive ingredients include asalyiatad monoglycarcs, ammovu Foxide bisckron crie, aspmdone, alicent dibchenate, tydhoxypropy ellioss, mpromeiose mannio Bropyono Gijcol, Sholac §1220, and e. The usual dosage information is provided in the package insert. The drug should be stored between 15°C to 30°C (59°F to 86°F) in a controlled room temperature. Keeping drugs out of reach of children is highly recommended. The manufacturer is American Health Packaging, Columbus, Ohio. The National Drug Code for Sevelamer Carbonate Tablets is 60687-328-65.*

This information represents the results of a study on the percentage of patients who experienced a reduction by 2 times in serum phosphorus levels (measured in mg/dL) after being treated with Sevelamer Hydrochloride, an active control medication. The table also includes information on whether the reduction improved or worsened from baseline.*

This appears to be a label or packaging information for Sevelamer Carbonate tablets with a strength of 800mg and an NDC number of 60687-328.31. The tablets are produced by American Health Packaging and distributed by AmerisourceBergen Company. The text also includes some tablet-related information, but the context is not clear.*

The text appears to be a chemical figure caption describing the chemical structure of Sevelamer Carbonate. It includes a diagram and labels with specific molecular groups and their numbers.*

This appears to be a chart showing the change in phosphorus levels from baseline over the course of a study week for a drug called Sevelamer Hydrochloride, which is being compared as an active-control to an unspecified alternative. The x-axis represents the study week, and the y-axis labels indicate the amount of change in phosphorus levels (in units that are not specified). The values on the chart appear to show an increase in phosphorus levels over time, with values of 22 at the baseline (presumably week 0) and 34 at week 38, with additional data points at weeks 26, 46, and 52. However, without more context it is difficult to interpret the significance of these findings.*